VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+59.81%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.46B
AUM Growth
+$1.46B
(+53%)
Cap. Flow
+$69.2M
Cap. Flow
% of AUM
4.75%
Top 10 Holdings %
Top 10 Hldgs %
68.34%
Holding
42
New
5
Increased
14
Reduced
8
Closed
6
Top Buys
| 1 |
Pharvaris
PHVS
|
$51.4M |
| 2 |
Spyre Therapeutics
SYRE
|
$44.7M |
| 3 |
Ocular Therapeutix
OCUL
|
$34.7M |
| 4 |
Arvinas
ARVN
|
$25.8M |
| 5 |
Astria Therapeutics
ATXS
|
$24.8M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$110M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$27.3M |
| 3 |
Travere Therapeutics
TVTX
|
$23.5M |
| 4 |
Savara
SVRA
|
$17.3M |
| 5 |
GH Research
GHRS
|
$8.27M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $251M | 17.19% | 4,030,471 +13,624 | +0.3% | +$847K |
|
2
Apogee Therapeutics
APGE
$2.17B
| $237M | 16.28% | 8,493,321 | – | – |
|
|
3
Pharvaris
PHVS
$1.39B
| $95.2M | 6.53% | 3,395,606 +1,832,093 | +117% | +$51.4M |
|
4
Viridian Therapeutics
VRDN
$1.5B
| $84.6M | 5.8% | 3,882,623 +800,001 | +26% | +$17.4M |
|
5
4D Molecular Therapeutics
FDMT
$288M
| $69.4M | 4.76% | 3,424,031 +424,031 | +14% | +$8.59M |
|
6
Merus
MRUS
$4.98B
| $59.1M | 4.05% | 2,148,214 +422,000 | +24% | +$11.6M |
|
7
Cabaletta Bio
CABA
$133M
| $58.2M | 3.99% | 2,563,952 +590,699 | +30% | +$13.4M |
|
|
8
Spyre Therapeutics
SYRE
$996M
| $51.1M | 3.5% | 2,372,714 +2,077,680 | +704% | +$44.7M |
|
9
KalVista Pharmaceuticals
KALV
$678M
| $50.1M | 3.44% | 4,092,731 +1,176,064 | +40% | +$14.4M |
|
10
Enliven Therapeutics
ELVN
$1.2B
| $40.9M | 2.8% | 2,954,902 | – | – |
|
|
11
Ocular Therapeutix
OCUL
$2.12B
| $34.7M | 2.38% | +7,775,760 | New | +$34.7M |
|
12
HilleVax
HLVX
$105M
| $33.3M | 2.28% | 2,075,000 +37,687 | +2% | +$605K |
|
|
AMAM
13
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $29.5M | 2.02% | 2,070,000 | – | – |
|
14
Terns Pharmaceuticals
TERN
$609M
| $29.2M | 2% | 4,497,117 +1,404,844 | +45% | +$9.12M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $28.9M | 1.98% | 2,173,913 | – | – |
|
16
Cogent Biosciences
COGT
$1.69B
| $27.5M | 1.89% | 4,684,167 | – | – |
|
17
Celcuity
CELC
$2.17B
| $27.5M | 1.88% | 1,885,538 -219,848 | -10% | -$3.2M |
|
18
Mersana Therapeutics
MRSN
$36.5M
| $26.3M | 1.8% | 11,328,000 | – | – |
|
|
19
Arvinas
ARVN
$568M
| $25.8M | 1.77% | +627,788 | New | +$25.8M |
|
|
20
Astria Therapeutics
ATXS
$349M
| $24.8M | 1.7% | +3,225,806 | New | +$24.8M |
|
|
21
Rhythm Pharmaceuticals
RYTM
$6.85B
| $22.8M | 1.56% | 495,983 -594,017 | -54% | -$27.3M |
|
22
Oric Pharmaceuticals
ORIC
$994M
| $22.3M | 1.53% | 2,428,385 +285,529 | +13% | +$2.63M |
|
23
Applied Therapeutics
APLT
$71M
| $20.9M | 1.44% | 6,250,000 +591,966 | +10% | +$1.98M |
|
24
Taysha Gene Therapies
TSHA
$797M
| $18.4M | 1.26% | 10,412,872 -4,031,572 | -28% | -$7.14M |
|
|
25
Savara
SVRA
$567M
| $16.5M | 1.13% | 3,500,000 -3,684,865 | -51% | -$17.3M |
|